 2 Annual Report 2017  |  EKF Diagnostics Holdings plc
1.0 Strategic Review
Financial and Operational Highlights
Financial Highlights
• Revenue up 8% to £41.6m (2016: £38.6m)
• Gross profit up 25% to £22.9m (2016: £18.3m)
• Adjusted EBITDA* up 52% to £9.3m (2016: £6.1m)
• Earnings per share of 0.59p (2016: nil)
• Cash generated from operations of £10.1m (2016: £8.8m)
• Cash at 31 December 2017 of £8.2m (31 Dec 2016: £7.9m),  
net cash of £7.0m (31 Dec 2016: £2.2m)
• Capital restructure creates distributable reserves and allows share buy back programme
* Excluding exceptional items and share based payments
Operational Highlights
• Continued effect of improvements to operational efficiency
• Closure of Polish operations brings sites down from twelve to seven
• Creation of Renalytix AI, Inc in January 2018 to exploit sTNFR technology
2017 Revenue
2012
2013
2014
2015
2016
2017
£26.1
£31.8
£37.1
£30.0
£38.6
£41.6
2017 2016 +/-
Revenue (£m) £41.6 £38.6 8%
Net cash (£m) £7.0 £2.2 218%
Adjusted  
EBITDA (£m)
£9.3 £6.1 52%
8%
increase in  
revenues year  
on year
£m
+10%
HEMOGLOBIN 
REVENUES
FY 2017 
£12,911 (£k)
FY 2016 
£11,704 (£k)
+5%
CENTRAL  
LABORATORY  
REVENUES
 FY 2017   
£12,597 (£k)
FY 2016 
£12,051 (£k)
+13%
DIABETES  
REVENUES
FY 2017 
£11,547 (£k)
FY 2016 
£10,203 (£k)
Annual revenues
*
*Restated
